RESUMO
Carbon capture technologies are becoming increasingly crucial in addressing global climate change issues by lowering CO2 emissions from industrial and power generation activities. Post-combustion carbon capture, which uses membranes instead of adsorbents, has emerged as one of promising and environmentally friendly approaches among these technologies. The operation of membrane technology is based on the premise of selectively separating CO2 from flue gas emissions. This provides a number of different benefits, including improved energy efficiency and decreased costs of operation. Because of its adaptability to changing conditions and its low impact on the surrounding ecosystem, it is an appealing choice for a diverse array of uses. However, there are still issues to be resolved, such as those pertaining to establishing a high selectivity, membrane degradation, and the costs of the necessary materials. In this article, we evaluate and explore the prospective applications and roles of membrane technologies to control climate change by post-combustion carbon capturing. The primary proposition suggests that the utilization of membrane-based carbon capture has the potential to make a substantial impact in mitigating CO2 emissions originating from industrial and power production activities. This is due to its heightened ability to selectively absorb carbon, better efficiency in energy consumption, and its flexibility to various applications. The forthcoming challenges and potential associated with the application of membranes in post-carbon capture are also discussed.
Assuntos
Mudança Climática , Resiliência Psicológica , Dióxido de Carbono , Ecossistema , CarbonoRESUMO
Insulin-like growth factor (IGF)-I is a ubiquitously synthesized peptide that, along with IGF-II, acts via the IGF-R type I receptor. IGF-I and its receptor are expressed in the adrenal gland of humans and bovines, the secretion of which they seem to stimulate. As in humans and cows, the main glucocorticoid hormone secreted by guinea-pig adrenals is cortisol, and hence we have studied the adrenocortical effects of IGF-I in this species. In vivo experiments showed that prolonged IGF-I administration raised the plasma concentration of cortisol in both normal and dexamethasone/captopril-treated guinea pigs, thereby ruling out the possibility that IGF-I may act by activating the hypothalamic-pituitary-adrenal axis and the renin-angiotensin system. In vitro experiments demonstrated that IGF-I enhanced basal, but not maximally agonist [ACTH and angiotensin-II (Ang-II)]-stimulated, cortisol secretion from freshly dispersed guinea-pig inner adrenocortical cells. The IGF-I immuno-neutralization suppressed the IGF-I secretagogue effect, without altering the cortisol response to both ACTH and Ang-II. IGF-I raised cyclic-AMP and inositol triphosphate release from dispersed guinea-pig cells, and the effect was reversed by the adenylate cyclase inhibitor SQ-22536 and the phospholipase-C (PLC) inhibitor U-73122. SQ-22536, U-73122, the protein kinase (PK) A inhibitor H-89 and the PKC inhibitor calphostin-C decreased by approximately 50% the cortisol response of dispersed cells to IGF-I, and the combined exposure to SQ-22536 and U-73122 abolished it. We conclude that IGF-I stimulates glucocorticoid secretion from guinea-pig adrenocortical cells, acting via selective receptors coupled to both the adenylate cyclase/PKA- and PLC/PKC-dependent signaling cascades.